ImmunityBio Inc (IBRX) Company Sales

Massive investments in vaccine development and NK-cell activation serve as the foundation for the growth of ImmunityBio, Inc. (IBRX). The company's commercial revenue on GURU.Markets reflects this progress, with the 0.18 metric acting as the target level. High brand authority among oncologists and the business's independence from economic cycles create a favorable backdrop for implementing breakthrough therapeutic strategies.

immunitybio.com (IBRX): Company Revenue from 07/04/2022 to 11/13/2026

Analytical breakdowns for ImmunityBio (IBRX)

- stock value and consensus price forecast:

Stock Quotes NantKwest|IBRX - Price Target Chart

- market capitalization details:

Market Valuation ImmunityBio, Inc.|IBRX - Real Price to Acquire Entire Company

- balance sheet equity data:

Book Value per Share ImmunityBio|IBRX - Company Book Value|Capitalization to Book Value Ratio immunitybio.com|IBRX - Aggregate Company Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

IBRX - Company Net Income|Expected Net Income ImmunityBio, Inc.|IBRX - P/E Multiple|Forward P/E Multiple immunitybio.com|IBRX - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio ImmunityBio, Inc.|IBRX - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months ImmunityBio|IBRX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months immunitybio.com|IBRX - Earnings per share growth in current year|Expected earnings per share growth for next year ImmunityBio, Inc.

- sales volume and revenue indicators:

IBRX - Company Revenue|Company Future Sales Volume NantKwest|IBRX - Market Cap to Revenue|Forward P/S Multiple ImmunityBio, Inc.

General company analysis:NantKwest, IBRX

ImmunityBio, Inc. (IBRX) operates in a segment characterized by colossal R&D expenditures and stringent FDA oversight, where commercial success is constrained by patent barriers. Daily revenue calculations establish an academic scale of real demand, allowing investors to distinguish speculative noise from long-term growth, which renders the company's sales financial dynamics a key tool for assessing the risk of capital freeze.

Key competitors